Treatment of Disorders Associated with G protein-Coupled Receptor 35 (GPR35)
Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation.
Citation
Abood, M., Zhao, P., Barak, L., & Seltzman, H. (2015). IPC No. U.S. Treatment of Disorders Associated with G protein-Coupled Receptor 35 (GPR35). (Patent No. 9040583).